We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

MMR (Measles, Mumps, Rubella) Vaccine Can Protect Against Severe COVID-19 Symptoms

By HospiMedica International staff writers
Posted on 22 Jun 2020
A team of experts have suggested that administering the MMR (measles, mumps, rubella) vaccine could serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection.

In their article published in the latest edition of mBio, a journal of the American Society for Microbiology, Dr. Paul Fidel, Jr., Department Chair, Oral and Craniofacial Biology, and Associate Dean for Research, Louisiana State University Health School of Dentistry and Dr. Mairi Noverr Professor of Microbiology & Immunology at Tulane University School of Medicine, have stated that vaccination with MMR in immunocompetent individuals has no contraindications and could be particularly effective for health care workers who are more exposed to COVID-19.

Illustration
Illustration

There is growing evidence that live attenuated vaccines provide non-specific protection against lethal infections unrelated to the target pathogen of the vaccine by inducing trained non-specific innate immune cells for improved host responses against subsequent infections. Live attenuated vaccines induce nonspecific effects representing “trained innate immunity” by training leukocyte (immune system cells) precursors in the bone marrow to function more effectively against broader infectious insults.

In their laboratory studies, the researchers found that vaccination with a live attenuated fungal strain-induced trained innate protection against lethal polymicrobial sepsis. The protection was mediated by long-lived myeloid-derived suppressor cells (MDSCs) previously reported inhibiting septic inflammation and mortality in several experimental models. According to the researchers, an MMR vaccine should be able to induce MDSCs that can inhibit or reduce the severe lung inflammation/sepsis associated with COVID-19. The researchers have proposed a clinical trial to test whether the MMR vaccine can protect against COVID-19, although in the meantime, they suggest that all adults, especially health care workers and individuals in nursing homes get the MMR vaccine.

“Live attenuated vaccines seemingly have some nonspecific benefits as well as immunity to the target pathogen. A clinical trial with MMR in high-risk populations may provide a low-risk-high-reward preventive measure in saving lives during the COVID-19 pandemic,” said Dr. Fidel. “While we are conducting the clinical trials, I don’t think it’s going to hurt anybody to have an MMR vaccine that would protect against the measles, mumps, and rubella with this potential added benefit of helping against COVID-19.”


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Ventilator
TRventi-3D

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles